DNAs from 1,3-butadiene-induced mammary adenocarcinomas of B6C3F1 mice were examined for mutations in the Trp53 gene, the ras gene family and several components of the Wnt signaling pathway, including bcatenin (Catnb), Apc and Axin. Trp53 mutations were detected in 41% (7 out of 17) of tumors. Each tumor with a Trp53 mutation also exhibited loss of the wildtype Trp53 allele, supporting the importance of Trp53 inactivation during development of these tumors. Analyses of the Hras1, Kras2 and Nras proto-oncogenes revealed Hras1 mutations in 53% (9 out of 17) of tumors. Seven of these mutations were a G?C transversion in Hras1 codon 13, consistent with a 1,3-butadiene-specific Kras2 mutation previously reported in several other tumor types. Mutation screens in Catnb exon 2, the Apc mutation cluster region and the Catnbbinding domain of the Axin gene identified Catnb missense mutations in 3 out of 17 (18%) tumors. In total, mutations of the Trp53, Hras1 and/or Catnb genes were identified in 15 out of 17 1,3-butadiene-induced mammary adenocarcinomas. These results indicate that multiple genetic pathways are disrupted in chemically induced mammary tumors, and that studies in mouse models may help to understand the etiology of human breast cancers.
Introduction
Breast cancer is the second most common cause of cancer-related mortality in women. Unfortunately, the etiology of breast cancer is still largely unknown. Carcinogenesis is clearly a multi-step process involving the accumulation of genetic alterations. Studies of human breast tumors have provided a great deal of data about the disruption of many different genetic pathways (Hartmann et al., 1997; Martin and Weber, 2000; Osborne and Hamshere, 2000; Thor et al., 1986) . However, human cancers are not ideal for mechanistic studies and experimentally induced mammary tumors of mice and rats have contributed a wealth of knowledge concerning the multi-step process of breast cancer development (Russo, 1996; Henninghausen, 2000) .
In this study we examined mammary adenocarcinomas that were induced in B6C3F1 mice by inhalation of 1,3-butadiene (BD) (Melnick et al., 1990) . BD is a potent multi-site carcinogen in B6C3F1 mice and a less strong carcinogen in F344 rats . It is used extensively in the production of synthetic rubber and is present in automotive exhaust and cigarette smoke (IARC, 1992) . Epidemiological evidence, together with results from rodent bioassays, have led to the listing of BD as 'known to be a human carcinogen' by the National Toxicology Program's Report on Carcinogens (National Toxicology Program, 2000) .
DNAs from BD-induced mammary adenocarcinomas (BMCs) were examined for mutations in the Trp53 gene, three ras gene family members and several components of the Wnt pathway, including the bcatenin (Catnb), Apc and Axin genes. Alterations in the human homologues of these genes have been found in many different tumor types including breast cancers. TP53 is a well-known tumor suppressor gene, whose functional inactivation has been detected in *40% of human breast cancers (Hartmann et al., 1997) . The ras proto-oncogenes (Hras1, Kras2 and Nras) encode related membrane-bound proteins and are involved in transmitting growth signals to the cell cycle machinery. These gene products can be activated by single amino acid substitution in codons 12, 13 or 61 and contribute to cellular transformation in a wide variety of human cancers as well as experimentally induced rodent tumors (Balmain and Brown, 1988; Bos, 1989) .
Activation of the Wnt signaling pathway has also been implicated in mammary carcinogenesis (Tsukamoto et al., 1988; Moser et al., 1993; Lin et al., 2000) . The ultimate result of Wnt pathway activation is the accumulation of free monomeric Catnb and in turn the activation of its target genes such as cyclin D1 (Ccnd1) and Myc (Lin et al., 2000; Korinek et al., 1997; Morin et al., 1997; Tetsu et al, 1999; He et al., 1998) . In the absence of Wnt signals, Catnb is phosphorylated, ubiquitinated and degraded by the proteasome pathway, keeping the levels of free Catnb low (Orford et al., 1999; Aberle et al., 1997; Miller et al., 1999) . GSK3b, Axin and Apc have been identified to directly promote the degradation of Catnb (Aberle et al., 1997; Miller et al., 1999; Morin, 1999; Hart et al., 1998) . Mutations in Apc, Axin, or the ubiquitination motif and GSK-3b phosphorylation sites of Catnb, which have been reported in different types of human and rodent tumors, appear to result in disruption of Catnb degradation and its consequent oncogenic activation Aberle et al., 1997; Miller et al., 1999; Morin, 1999; Rubinfeld et al., 1997; Polakis, 1995; Satoh et al., 2000; Dashwood et al., 1998; Devereux et al., 1999; de La Coste et al., 1998) .
Results

Mutation analysis of the Trp53 gene
Genomic DNAs from 17 BMCs were examined by PCR-based single strand conformation analysis (SSCA) and direct DNA sequencing to determine the frequency and nature of mutations in the Trp53 gene. Missense mutations were detected in 6 out of 17 (35%) BMCs and one tumor (BMC 8) displayed distinct base substitutions in codons 247 and 250 (Table 1 and Figure 1 ). An internal homozygous deletion of Trp53 gene was also previously detected in one of these tumors (BMC 2) (Wiseman et al., 1994) . As expected, all seven tumors with Trp53 mutations also exhibited loss of heterozygosity (LOH) at the Acrb locus that lies within 1 cM of Trp53 ( Figure 1 Sequence analysis of Trp53 mutations. Sequence of Trp53 exon 8 for non-coding strands are shown. Arrows, mutated bases. BMC 8 showed mutations in both codons 247 and 250. F1, DNA that was derived from normal B6C3F1 mice displayed wildtype sequence 53% (9 out of 17) of the tumors examined (Table 1) . No mutations were identified in the Kras2 or Nras genes. Interestingly, 7 of these 9 Hras1 mutations were a G?C transversion at the first base of codon 13, which resulted in an amino acid substitution (Gly to Arg; Table 1 and Figure 2 ). Furthermore, all but one tumor with Hras1 mutations were observed in the lower exposure groups (4200 p.p.m., Table 1 ). Figure 3 ). These Catnb mutations were clustered in the domain that contains a ubiquitination motif (codons 32 -37) and four conserved GSK-3b phosphorylation sites (Ser33, Ser37, Thr41, and Ser45).
As with the Hras1 mutations, these three tumors were derived from mice exposed to 4200 p.p.m. of BD (Table 1) . These results indicate that mutations of the Catnb gene are involved in at least a subset of BMC development. Oncogenic activation of Catnb can also be achieved by functional loss of Apc that promotes degradation of Catnb. Inactivation of Apc by point mutations has been found in different types of cancers (Polakis et al, 1995) . The mutations are clustered in the central region of the Apc gene (approximately codons 1280 -1500), which contains binding sites for Catnb. Apc deletion mutants, which truncate the protein across the mutational cluster region, lost or had reduced ability to associate with Catnb and to promote its degradation (Rubinfeld et al., 1997) . Although LOH on chromosomal region containing the Apc gene was observed in 5 out of 17 BMC tumors (Wiseman et al., 1994) , no mutations were identified in the region of Apc examined (data not shown). Likewise, none of the BMCs examined had genetic alterations in the Catnb binding site (codons 561 -631) of the Axin gene (data not shown).
Discussion
It is well known that TP53 inactivation is involved in the development of a variety of human malignancies including breast cancer. The most common mechanism underlying functional loss of TP53 is point mutations in one allele followed by LOH in the remaining wildtype allele. About 90% of reported mutations are localized within exons 5 -8, a domain of TP53 that has been highly conserved through evolution and is functionally significant (Greenblatt et al., 1994) . In the present study, we have identified genetic alterations of the Trp53 gene in 7 out of 17 (41%) BMCs, which is comparable to the frequency of TP53 mutations in human breast cancers (Hartmann et al., 1997) . All tumors carrying Trp53 mutations also displayed loss of the wild-type Trp53 allele, supporting the importance of functional loss of Trp53 during development of these tumors. Point mutations in exons 5 -8 of the Trp53 gene were not detected in five BMCs with LOH on chromosome 11 (Table 1) . While it is possible that inactivating Trp53 mutations lie outside the exons examined, these LOH events may also reflect random chromosomal alterations or the selection for loss of the other genes located on chromosome 11.
Missense mutations in the Hras1 gene were found in 9 out of 17 (53%) BMCs. All mutations found were located to codons 12, 13 or 61, the critical sites that are Figure 2 Sequence analysis of Hras1 mutation. Sequence of Hras1 exon 1 for non-coding strand is shown. The BMC tumor carried a mutation in codon 13. Arrow, mutated base Figure 3 Sequence analysis of Catnb mutations. Sequences of Catnb exon 2 for coding strands are shown. BMC 9 and 11 showed mutations in codons 41 and 33, respectively, whereas BMC 17 contained a mutation at codon 34. F1, DNA that was derived from normal B6C3F1 mice displayed wild-type sequence.
Arrows, mutated bases
Genetic alterations in 1,3-butadiene-induced mammary tumors S-M Zhuang et al frequently mutated in different types of tumors (Balmain and Brown, 1988; Bos, 1989) . Interestingly, 7 out of these 9 Hras1 mutations were a G?C transversion in the first base of codon 13, which resulted in Gly to Arg substitution. Analogous Kras2 codon 13 G?C mutations have been observed frequently in BD-induced lymphomas (Zhuang et al., 1997) , lung adenocarcinomas (Goodrow et al., 1990) , hepatocellular carcinomas (Goodrow et al., 1990) , hemangiosarcomas (Hong et al., 2000) and forestomach tumors ). This G?C mutation in codon 13 of the Hras1 and Kras2 genes is rarely found in spontaneous or other chemicallyinduced mouse tumors as well as human tumors (Balmain and Brown, 1988; Sills et al., 2001) . Unfortunately, no mammary adenocarcinomas were observed in untreated B6C3F1 mice from the original study (Melnick et al., 1990 ), so we were unable to determine the frequency and spectrum of Hras1 mutation in spontaneously occurring mammary tumors. This specific G?C base substitution may result from a direct interaction of reactive epoxide metabolites of BD with the Ras genes. In a recent report, the proportion of G?C transversions in exon three of the endogenous Hprt gene was significantly increased in BD-exposed versus control B6C3F1 mice (Meng et al., 2000) . This hypothesis is also supported by the finding that BD-metabolized epoxide intermediates are genotoxic and alkylate DNA both in vitro and in vivo, mainly at the N7 position of guanine (Koivisto et al., 1999) . It seems that Kras2 and Hras1 genes are preferentially mutated in different types of BDinduced tumors, which may reflect the differential expression of the Kras2 and Hras1 genes in different tissues (Balmain and Brown, 1988; Leon et al., 1987) .
In contrast to the specific Ras codon 13 G?C transversion mutation, a variety of Trp53 alterations were observed in these mammary tumors. These observations are consistent with previous data from BD-induced lymphomas of B6C3F1 mice (Zhuang et al., 1997) . This phenomenon may reflect the greater target size for Trp53 versus Ras alterations during oncogenesis. Specific amino acid substitutions in codons 12, 13 and 61 of the Ras genes contribute to cellular transformation, whereas many different sites within the Trp53 gene can be mutated to result in tumorigenesis.
Analysis of the Catnb gene revealed that 18% (3 out of 17) of BMCs carried point mutations in codons 33, 34 or 41, sites also shown to be frequently mutated in various types of human, mouse and rat tumors (Miller et al., 1999; Morins, 1999; Dashwood et al., 1998; Devereux et al., 1999; de La Coste et al., 1998) . Mutations in codons 33 and 41 affect the serine and threonine residues targeted for phosphorylation by GSK-3b. Codon 34 is located within the ubiquitination motif and mutation of this codon may affect phosphorylation-dependent ubiquitination and subsequent degradation of Catnb (Morin, 1999) . It has been demonstrated that point mutations in these codons result in accumulation of a highly stable form of Catnb that is constitutively active and forms complexes with T-cell transcription factors (Tcf) de La Coste et al., 1998) . These complexes in turn stimulate expression of its target genes that are involved in different cellular functions. Dysregulation of Catnb/Tcf target gene expression is considered to be a critical event in the malignant transformation. Recent identification of Ccnd1 and Myc as direct downstream targets of Catnb/Tcf may also provide some insights into the role of Catnb in tumorigenesis (Lin et al., 2000; Tetsu et al, 1999; He et al., 1998) . Both Myc and Ccnd1 are proto-oncogenes that promote the G1/S phase transition and subsequently cell proliferation. Exogenous Catnb expression has also been shown to attenuate the G1 phase cell cycle arrest triggered by DNA damage and to protect the cell from undergoing apoptosis (Orford et al., 1999) . Thus, mutations in the Catnb gene that result in accumulation of its coding protein may lead to tumorigenesis by stimulating cell proliferation or preventing apoptosis. In addition, elevated Catnb expression may enhance the accumulation of additional mutations by preventing the DNA damage-induced arrest of the cell cycle.
Inactivation of Trp53 by mutations was observed in 4 out of 5 BMCs derived from the 625 p.p.m. exposure group, compared to 3 out of 12 BMC from 4200 p.p.m. groups (Table 1 ). In contrast, 11 out of 12 tumors with Hras1 or Catnb mutations were collected from lower dose groups (4200 p.p.m.). Although we cannot do statistical analysis because of too small sample numbers in the 625 p.p.m. group, it is worthwhile to notice that similar correlation between exposure doses and mutations of the Trp53 or Ras genes have also been observed in BD-induced lymphomas (Zhuang et al., 1997) .
In total, we detected genetic alterations in the Trp53, Hras1 or Catnb genes in 15 out of 17, 1,3-butadieneinduced mammary adenocarcinomas. The human homologues of these genes (TP53, HRAS and CTNNB1) are frequently mutated in diverse forms of human cancers. Frequent mutations of TP53 have also been detected in human breast cancers (Hartmann et al., 1997) . Although mutations in HRAS and CTNNB1 are rarely found in human mammary malignancies, enhanced HRAS expression in both protein and mRNA levels has been observed (Thor et al., 1986) . Activation of the Wnt/b-catenin pathway has also been implicated in mammary carcinogenesis (Tsukamoto et al., 1988; Moser et al., 1993; Lin et al., 2000) .
Our results indicate that disruption of the Trp53, Ras and Wnt/b-catenin pathways are involved in the development of chemically induced mammary tumors, and the studies in mouse models may help to understand the mechanisms underlying chemical carcinogenesis as well as the etiology of human breast cancers.
Materials and methods
Tumor induction and DNA isolation
Tumors were induced in B6C3F1 mice by up to 2 years inhalation of 6.25 -625 p.p.m. of BD as reported previously (Melnick et al., 1990) . BMCs were collected from 17 female mice (Table 1) and DNAs were isolated from frozen tumor samples as described previously (Wiseman et al., 1994) .
Analysis of point mutations in the Trp53, Ras, Catnb, Apc, and Axin genes PCR-SSCA and direct DNA sequencing were employed for point mutation analysis. Primers for analysis of the Trp53 gene exons 5 -8 and the Hras1, Kras2, and Nras genes exons 1 -2 have been reported previously (Zhuang et al., 1997) . Primers used for mutation analysis in exon 2 of the Catnb gene, the region containing GSK-3b-targeted phosphorylation residues and ubiquitination motif, have been described by de La Coste et al. (1998) . Five sets of primers used to amplified codons 1228 -1547 of exon 15 of the Apc gene and one set of primers for Catnb-binding domain of the Axin gene were listed in Table 2 . An annealing temperature of 55 -608C was used for PCR reactions. SSCA were performed as described previously (Zhuang et al., 1997) . PCR fragments demonstrating altered electrophoretic mobility by SSCA were eluted from the gel, reamplified in a 50-ml PCR mix, and purified with GFX PCR DNA and Gel Band Purification Kit (Amersham Pharmacia Biotech, Buckinghamshire, UK). Double-stranded DNA was sequenced with a Thermo Sequenase radiolabeled terminator cycle sequencing kit, following the manufacturer's instruction (Amersham Pharmacia Biotech). 
